The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ECOG 1808: Randomized phase II trial of sunitinib with or without gemcitabine in advanced kidney cancer with sarcomatoid features.
 
Naomi B. Haas
Stock and Other Ownership Interests - TetraLogic Pharmaceuticals (I)
Expert Testimony - Lilly (I)
 
Maneka Puligandla
No Relationships to Disclose
 
David F. McDermott
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; exelixis; Genentech/Roche; Merck; Novartis; Pfizer; X4 Pharma
Research Funding - Prometheus (Inst)
 
Janice P. Dutcher
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Merck; Novartis; Pfizer; Prometheus; TRACON Pharma
Speakers' Bureau - Novartis; Pfizer; Prometheus
Travel, Accommodations, Expenses - Merck; Novartis; Pfizer; Prometheus
 
Judith Manola
No Relationships to Disclose
 
Michael Pins
Speakers' Bureau - Genentech/Roche; Pfizer
 
Michael Anthony Carducci
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Blue Earth Diagnostics; Clovis Oncology; Medivation; Merck
 
Jacqueline Vuky
No Relationships to Disclose
 
Bradley Curtis Carthon
No Relationships to Disclose
 
Elizabeth R. Plimack
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Dendreon; Genentech/Roche; GlaxoSmithKline; Merck; Novartis; Pfizer
Research Funding - Acceleron Pharma (Inst); Acerta Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)
 
Leonard Joseph Appleman
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Cerulean Pharma; Exelixis
 
Henry C. Pitot
No Relationships to Disclose
 
Timothy Kuzel
Honoraria - Amgen; Argos Therapeutics; Astellas Pharma; Bayer/Onyx; Bionomics; Celgene; Eisai; Genentech/Roche; Janssen
Speakers' Bureau - Astellas Pharma; Bayer; Celgene; Genentech/Roche; Janssen Oncology
Research Funding - Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); CureTech (Inst); Eisai (Inst); Genentech/Roche (Inst); MedImmune (Inst); Merck/Schering Plough (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Argos Therapeutics; Astellas Pharma; Bayer/Onyx; Celgene; elorac; Genentech; Janssen Oncology
 
Robert S. DiPaola
Research Funding - Abbvie (Inst)